检索
AI 对话
analysis
趋势分析
编组
开放平台
more
更多
排名必读论文期刊顶会热点AI 简史溯源树小脉星探人才迁徙塔尖人才国防情报追踪开源工具智慧手语
VIPCreated with Sketch.

Plain language summary of the CheckMate 816 study results: nivolumab plus chemotherapy given before surgery for non-small-cell lung cancer.

Patrick M Forde,Jonathan Spicer,Shun Lu,Mariano Provencio,Tetsuya Mitsudomi,Mark M Awad,Enriqueta Felip,Stephen R Broderick,Julie R Brahmer,Scott J Swanson,Keith Kerr,Changli Wang,Tudor-Eliade Ciuleanu,Gene B Saylors,Fumihiro Tanaka,Hiroyuki Ito,Ke Neng Chen,Moishe Liberman,Everett E Vokes,Janis M Taube,Cecile Dorange,Junliang Cai,Joseph Fiore,Anthony Jarkowski,David Balli,Mark Sausen,Dimple Pandya,Christophe Y Calvet,Nicolas Girard

Future oncology (London, England)（2023）

引用 0|浏览51
暂无评分
摘要
Results from CheckMate 816 support the benefit of using before surgery for people with resectable NSCLC. : NCT02998528 (ClinicalTrials.gov).
更多
查看译文
关键词
clinical trial,immunotherapy,lay summary,neoadjuvant treatment,nivolumab,non–small cell lung cancer,plain language summary,presurgery treatment
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要